Newly Identified Markers May Predict Who Will Respond To Breast Cancer Prevention Therapy

Genetic variations, known as single nucleotide polymorphisms (SNPs), in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research. Women who have the favorable variations of these two SNPs are more likely to respond to prevention therapy, according to this study...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Breast Cancer Source Type: news